1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Illumina, Inc.
  6. Summary
    ILMN   US4523271090

ILLUMINA, INC.

(ILMN)
  Report
Real-time Estimate Cboe BZX  -  12:44 2022-07-06 pm EDT
195.53 USD   +1.30%
07/05Evercore ISI Adjusts Illumina's Price Target to $180 From $280, Maintains In Line Rating
MT
06/28Community Health Network and Grail Partner to Offer Galleri® Multi-Cancer Early Detection Test in Central Indiana
BU
06/28Illumina Invests in £30M Venture Fund to Advance Breakthroughs in Human Health
PR
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/29/2022 06/30/2022 07/01/2022 07/05/2022 07/06/2022 Date
186.43(c) 184.36(c) 191.04(c) 193.02(c) 195.245 Last
1 223 271 1 243 710 1 118 163 1 104 083 578 627 Volume
-0.53% -1.11% +3.62% +1.04% +1.15% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 5 203 M - -
Net income 2022 449 M - -
Net cash position 2022 557 M - -
P/E ratio 2022 65,9x
Yield 2022 -
Sales 2023 6 027 M - -
Net income 2023 738 M - -
Net cash position 2023 1 628 M - -
P/E ratio 2023 42,3x
Yield 2023 -
Capitalization 30 323 M 30 323 M -
EV / Sales 2022 5,72x
EV / Sales 2023 4,76x
Nbr of Employees 9 825
Free-Float 79,4%
More Financials
Company
Illumina, Inc. specializes in the development, manufacturing and marketing of integrated systems for the analysis of genetic variation and biological function. The group's products are for genomic research centers, pharmaceutical companies, university institutions, clinical research organizations, and biotechnology companies. Net sales break down by source of income as follows: - product sales (87.7%): tools and... 
More about the company
Ratings of Illumina, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about ILLUMINA, INC.
07/05Evercore ISI Adjusts Illumina's Price Target to $180 From $280, Maintains In Line Ratin..
MT
06/28Community Health Network and Grail Partner to Offer Galleri® Multi-Cancer Early Detecti..
BU
06/28Illumina Invests in £30M Venture Fund to Advance Breakthroughs in Human Health
PR
06/24ILLUMINA, INC.(NASDAQGS : ILMN) added to Russell 3000 Value Index
CI
06/24ILLUMINA, INC.(NASDAQGS : ILMN) dropped from Russell 1000 Defensive Index
CI
06/24ILLUMINA, INC.(NASDAQGS : ILMN) dropped from Russell 1000 Growth-Defensive Index
CI
06/24ILLUMINA, INC.(NASDAQGS : ILMN) added to Russell Top 200 Value Index
CI
06/24ILLUMINA, INC.(NASDAQGS : ILMN) dropped from Russell 3000 Growth Index
CI
06/24ILLUMINA, INC.(NASDAQGS : ILMN) added to Russell 3000E Value Index
CI
06/24ILLUMINA, INC.(NASDAQGS : ILMN) dropped from Russell 3000E Growth Index
CI
06/24ILLUMINA, INC.(NASDAQGS : ILMN) added to Russell 1000 Value Index
CI
06/24ILLUMINA, INC.(NASDAQGS : ILMN) dropped from Russell Top 200 Growth Index
CI
06/24ILLUMINA, INC.(NASDAQGS : ILMN) dropped from Russell 1000 Growth Index
CI
06/22Illumina Launches Research Test Codeveloped with Merck to Unlock Deeper Insights into t..
PR
06/22Illumina Launches Research Test Codeveloped with Merck to Unlock Deeper Insights into t..
CI
More news
News in other languages on ILLUMINA, INC.
06/22Illumina lance un test de recherche développé en collaboration avec Merck pour mieux co..
06/10Les actions américaines en forte baisse vendredi après des données plus élevées que pré..
06/10Les actions américaines chutent vendredi en raison de données plus élevées que prévu su..
06/10Les actions chutent en milieu de journée après le rapport sur l'inflation de mai
06/10RAPPORT DE LA MI-JOURNÉE : Les actions américaines chutent après le rapport sur l'inflatio..
More news
Analyst Recommendations on ILLUMINA, INC.
More recommendations
Chart ILLUMINA, INC.
Duration : Period :
Illumina, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ILLUMINA, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 193,02 $
Average target price 352,88 $
Spread / Average Target 82,8%
EPS Revisions
Managers and Directors
Francis A. deSouza President, Chief Executive Officer & Director
Sam A. Samad Chief Financial Officer & Senior Vice President
John Wendell Thompson Chairman
Phillip G. Febbo Chief Medical Officer
Alex Aravanis CTO, Head-Research & Product Development
Sector and Competitors